Trial Profile
A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study to Compare the Efficacy and Safety of Sotatercept (ACE-011) Versus Placebo When Added to Standard of Care for the Treatment of Pulmonary Arterial Hypertension (PAH)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 May 2023
Price :
$35
*
At a glance
- Drugs Sotatercept (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions; Therapeutic Use
- Acronyms PULSAR
- Sponsors Acceleron Pharma
- 30 Aug 2022 Results published in the European Respiratory Journal
- 03 May 2022 Status changed from active, no longer recruiting to completed.
- 10 Mar 2022 Planned End Date changed from 16 May 2022 to 18 Apr 2022.